Sofinnova group (NASDAQ: COAG) discloses 5.4% Hemab Therapeutics ownership on Schedule 13G

Rhea-AI Filing Summary

Hemab Therapeutics Holdings, Inc. has a significant shareholder group led by Sofinnova. Sofinnova Crossover II SLP, together with Sofinnova Partners SAS and the members of Sofinnova’s investment committee, report beneficial ownership of 2,511,212 shares of common stock of Hemab.

This holding represents 5.4% of the common stock, with ownership stated as of June 30, 2026. The percentage is based on 46,705,410 shares outstanding as of May 8, 2026, as disclosed by Hemab. The Sofinnova entities may be deemed to have sole voting and dispositive power over these shares, while the investment committee members may be deemed to share such powers, though they expressly disclaim being beneficial owners for certain legal purposes.

Key Figures

Beneficially owned shares: 2,511,212 shares Percent of class: 5.4% Shares outstanding baseline: 46,705,410 shares

3 metrics

Beneficially owned shares 2,511,212 shares Shares of Hemab Therapeutics common stock reported by the Sofinnova filing persons

Percent of class 5.4% Ownership percentage of Hemab common stock as of June 30, 2026

Shares outstanding baseline 46,705,410 shares Hemab common stock outstanding as of May 8, 2026, per Form 10-Q

Key Terms

beneficial owner, dispositive power, voting power, Schedule 13G, +1 more

5 terms

beneficial owner regulatory

"the beneficial owner of any securities covered by this Statement"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

dispositive power regulatory

"sole power to dispose or to direct the disposition of"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

voting power regulatory

"sole power to vote or to direct the vote"

Voting power is the ability shareholders have to influence a company's major decisions—like electing the board, approving mergers, or changing corporate rules—based on the voting rights attached to the shares they hold. For investors it matters because greater voting power is like holding more keys to a building: it gives you a stronger say over management choices and the company’s strategy, which can affect future value and risk.

Schedule 13G regulatory

"the persons and entities filing this are Sofinnova Crossover II SLP"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

CUSIP Number financial

"CUSIP Number(s): 423494103"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 10:38 AM Accepted by SEC EDGAR 08/05/2026 - 10:38 AM Learn about SEC filing dates

FAQ

What stake in COAG does Sofinnova report on this Schedule 13G?

Sofinnova and related filing persons report beneficial ownership of 2,511,212 shares of Hemab Therapeutics Holdings, Inc. common stock, representing 5.4% of the outstanding shares based on the issuer’s reported share count.

How is the 5.4% ownership in COAG calculated?

The 5.4% figure is based on 2,511,212 shares beneficially owned out of 46,705,410 shares of Hemab common stock outstanding as of May 8, 2026, as disclosed in Hemab’s Form 10-Q filed May 21, 2026.

Who are the filing persons on this Hemab (COAG) Schedule 13G?

The filing persons are Sofinnova Crossover II SLP, Sofinnova Partners SAS, and investment committee members Antoine Papiernik, Cedric Moreau, Kinam Hong, Joseph Anderson, and David Evans, collectively referred to as the Filing Persons.

What voting and dispositive power does Sofinnova report over COAG shares?

Sofinnova Crossover II SLP and Sofinnova Partners SAS report sole voting power and sole dispositive power over 2,511,212 shares. The investment committee members may be deemed to share voting and dispositive power through their roles on the committee.

As of what dates are the COAG ownership figures in this Schedule 13G stated?

Ownership is stated as of June 30, 2026, while the percentage of class is based on 46,705,410 shares outstanding as of May 8, 2026, as reported in Hemab’s Form 10-Q filed May 21, 2026.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Hemab Therapeutics Holdings, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

423494103

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

Sofinnova Crossover II SLP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,511,212.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,511,212.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,511,212.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Note to Items 5 and 6: Sofinnova Partners SAS, a French corporation ("SP SAS"), the management company of Sofinnova Crossover II SLP ("SC"), may be deemed to have sole voting power, and Antoine Papiernik ("Papiernik"), Cedric Moreau ("Moreau"), Kinam Hong ("Hong"), Joseph Anderson ("Anderson") and David Evans ("Evans") the members of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, Moreau, Hong, Anderson and Evans, the members of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 9 and 11: The aggregate amount beneficially owned and percent of class reported above are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 21, 2026.

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

Sofinnova Partners SAS, a French corporation

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,511,212.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,511,212.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,511,212.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and the members of the investment committee of SC, may be deemed to have shared power to vote its shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and the members of the investment committee of SC, may be deemed to have shared power to dispose of its shares. Note in relation to Items 9 and 11: The aggregate amount beneficially owned and percent of class reported above are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 21, 2026.

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

Antoine Papiernik

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,511,212.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,511,212.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,511,212.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 9 and 11: The aggregate amount beneficially owned and percent of class reported above are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 21, 2026.

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

Cedric Moreau

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,511,212.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,511,212.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,511,212.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 9 and 11: The aggregate amount beneficially owned and percent of class reported above are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 21, 2026.

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

Kinam Hong

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,511,212.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,511,212.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,511,212.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Hong, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Hong, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 9 and 11: The aggregate amount beneficially owned and percent of class reported above are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 21, 2026.

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

Joseph Anderson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,511,212.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,511,212.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,511,212.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 9 and 11: The aggregate amount beneficially owned and percent of class reported above are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 21, 2026.

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

David Evans

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,511,212.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,511,212.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,511,212.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Note to Items 5 and 6: SP SAS, the management company of SC, may be deemed to have sole voting power, and Evans, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Evans, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 9 and 11: The aggregate amount beneficially owned and percent of class reported above are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 21, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Hemab Therapeutics Holdings, Inc.
(b)	Address of issuer's principal executive offices: 101 Main Street Suite 1220 Cambridge, MA, 02142
Item 2.
(a)	Name of person filing: The persons and entities filing this Schedule 13G are Sofinnova Crossover II SLP ("SC"), Sofinnova Partners SAS ("SP SAS"), and Antoine Papiernik ("Papiernik"), Cedric Moreau ("Moreau), Kinam Hong ("Hong"), Joseph Anderson ("Anderson") and David Evans ("Evans"), the members of the investment committee of SC, (together with SC and SP SAS, the "Filing Persons"). SP SAS is the management company of SC.
(b)	Address or principal business office or, if none, residence: The address of the principal place of business for each of the Filing Persons is Sofinnova Partners SAS, 7-11 boulevard Hausmann 75009 Paris, France.
(c)	Citizenship: SC is a French Partnership. SP SAS is a French Corporation. Papiernik, Moreau and Evans are French citizens. Hong is a U.S. citizen. Anderson is a British citizen.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 423494103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of the cover page for each of the Filing Persons, which is incorporated herein by reference. The filing of this Schedule 13G shall not be construed as an admission by Papiernik, Moreau, Hong, Anderson and Evans that such person is, for the purposes of Section 13(d) of the Securities Exchange Act of 1934, the beneficial owner of any securities covered by this Statement.
(b)	Percent of class: See Row 11 of the cover page for each of the Filing Persons, which is incorporated herein by reference. Ownership is stated as of June 30, 2026, and the ownership percentages are based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as disclosed by Hemab Therapeutics, Inc. in its Form 10-Q filed with the SEC on May 21, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of the cover page for each of the Filing Persons, which is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: See Row 6 of the cover page for each of the Filing Persons, which is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of the cover page for each of the Filing Persons, which is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of the cover page for each of the Filing Persons, which is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sofinnova Crossover II SLP

Signature:	Antoine Papiernik
Name/Title:	Managing Partner
Date:	08/05/2026

Sofinnova Partners SAS, a French corporation

Signature:	Antoine Papiernik
Name/Title:	Managing Partner
Date:	08/05/2026

Antoine Papiernik

Signature:	Antoine Papiernik
Name/Title:	Antoine Papiernik
Date:	08/05/2026

Cedric Moreau

Signature:	Cedric Moreau
Name/Title:	Cedric Moreau
Date:	08/05/2026

Kinam Hong

Signature:	Kinam Hong
Name/Title:	Kinam Hong
Date:	08/05/2026

Joseph Anderson

Signature:	Joseph Anderson
Name/Title:	Joseph Anderson
Date:	08/05/2026

David Evans

Signature:	David Evans
Name/Title:	David Evans
Date:	08/05/2026

Exhibit Information

Exhibit 1 - Joint Filing Agreement